TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426

Cancer burden in the year 2000. The global picture

Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169

DECLARATION OF HELSINKI.

Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

Ou, S.-H. I. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.010 · Cited by 182

Cellular responses to EGFR inhibitors and their relevance to cancer therapy

Dutta, P. R., & Maity, A. M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.006 · Cited by 185

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Cheng, Y., Murakami, H., Yang, P., He, J., Nakagawa, K., Kang, J. H., Kim, J.-H., Wang, X., Enatsu, S., Puri, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9218 · Cited by 182

Models for prevention and treatment of cancer: Problems vs promises

Aggarwal, B. B., Danda, D., Gupta, S. R., & Gehlot, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.027 · Cited by 184

EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms

Baumann, M. A., Krause, M., Dikomey, E., Dittmann, K., Dörr, W., Kasten-Pisula, U., & Rodemann, H. P. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.04.006 · Cited by 179

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

Marshall, J. L. (2006) · Cancer · doi:10.1002/cncr.22133 · Cited by 178

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00204 · Cited by 179

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

Halatsch, M., Schmidt, U. I., Behnke‐Mursch, J., Unterberg, A. W., & Wirtz, C. R. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.01.003 · Cited by 172

Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer

Stewart, D. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.11.006 · Cited by 175

Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications

Rudin, C. M., Ávila-Tang, É., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W. J., Schwartz, A. G., Vähäkangas, K., & Samet, J. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0377 · Cited by 175

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Manegold, C., Gravenor, D. S., Woytowitz, D., Mezger, J. M., Hirsh, V., Albert, G. R., Al-Adhami, M., Readett, D., Krieg, A. Μ., & Leichman, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5807 · Cited by 170

Treatment of Non-small Cell Lung Cancer, Stage IV

Socinski, M. A., Crowell, R. E., Hensing, T., Langer, C. J., Lilenbaum, R., Sandler, A. B., & Morris, D. (2007) · CHEST Journal · doi:10.1378/chest.07-1381 · Cited by 169

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

Linger, R. M. A., Keating, A. K., Earp, H. S., & Graham, D. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.515980 · Cited by 171

The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression

Dong, S., Qu, X., Li, W., Zhong, X., Li, P., Yang, S., Chen, X., Shao, M., & Zhang, L. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0140-6 · Cited by 165

Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis

Rusthoven, K. E., Hammerman, S. F., Kavanagh, B. D., Birtwhistle, M. J., Stares, M. D., & Camidge, D. R. (2009) · Acta Oncologica · doi:10.1080/02841860802662722 · Cited by 165

Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

Goeckenjan, G., Sitter, H., Thomas, M., Branscheid, D., Flentje, M. P., Griesinger, F., Niederle, N., Stuschke, M., Blum, T. G., Deppermann, K., et al. (2010) · Pneumologie · doi:10.1055/s-0029-1243837 · Cited by 166

EGFR, HER2 and VEGF Pathways

Press, M. F., & Lenz, H. (2007) · Drugs · doi:10.2165/00003495-200767140-00006 · Cited by 172

Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics

Sarker, D., & Workman, P. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 162

Erlotinib in cancer treatment

Bareschino, M., Schettino, C., Troiani, T., Martinelli, E., Morgillo, F., & Ciardiello, F. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm222 · Cited by 163

Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review

Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0405 · Cited by 164

Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing SomaticEGFRMutation Testing

Sequist, L. V. D., Joshi, V. A., Janne, P. A., Muzikansky, A., Fidias, P. M., Meyerson, M. M., Haber, D. A., Kucherlapati, R., Johnson, B. E., & Lynch, T. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-90 · Cited by 161

Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas

Karamouzis, M. V., Grandis, J. R., & Argiris, A. E. (2007) · JAMA · doi:10.1001/jama.298.1.70 · Cited by 163

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Clark, G. M., Zborowski, D. M., Santabarbara, P., Ding, K., Whitehead, M., Seymour, L., & Shepherd, F. A. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.022 · Cited by 158

Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

Giovannetti, E., Lemos, C., Tekle, C., Smid, K., Nannizzi, S., Rodríguez, J. A., Ricciardi, S., Danesi, R., Giaccone, G., & Peters, G. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.042382 · Cited by 158

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

Sequist, L. V. D., & Lynch, T. J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.59.090506.202405 · Cited by 156

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

Santos, G. D. C., Dhani, N. C., Tu, D., Chin, K., Ludkovski, O., Kamel‐Reid, S., Squire, J. A., Parulekar, W. R., Moore, M. J., & Tsao, M. (2010) · Cancer · doi:10.1002/cncr.25393 · Cited by 157

Treatment of advanced non small cell lung cancer.

Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 161

Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Calvo, E., & Baselga, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5961 · Cited by 155

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

Zhang, J., Kalyankrishna, S., Wislez, M., Thilaganathan, N., Saigal, B., Wei, W., Ma, L., Wistuba, I., Johnson, F., & Kurie, J. (2007) · American Journal of Pathology · doi:10.2353/ajpath.2007.060706 · Cited by 154

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

Murray, S. J., Dahabreh, I. J., Linardou, H., Manoloukos, M., Bafaloukos, D. I., & Kosmidis, P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818071f3 · Cited by 154

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Jänne, P. A., & Johnson, B. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0555 · Cited by 147

Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer

Robert, F., Blumenschein, G., Herbst, R. S., Fossella, F. V., Tseng, J. E., Saleh, M. N., & Needle, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1438 · Cited by 150

Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

Siu, L. L., Soulières, D., Chen, E. X., Pond, G. R., Chin, S. F., Francis, P., Harvey, L., Klein, M., Zhang, W., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.6547 · Cited by 149

Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments

Steeghs, N., Nortier, J. W. R., & Gelderblom, H. A. J. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9227-1 · Cited by 147

The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support

Warren, G. W., Sobus, S. L., & Gritz, E. R. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70266-9 · Cited by 147

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.239 · Cited by 145

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 143

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures

Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142

Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea

Gerber, D. E., & Schiller, J. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7459 · Cited by 141

Current Treatments for Advanced Stage Non-Small Cell Lung Cancer

Stinchcombe, T. E., & Socinski, M. A. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-110lc · Cited by 141

Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

Han, B., Jin, B., Chu, T., Niu, Y., Dong, Y., Xu, J., Gu, A., Zhong, H., Wang, H., Zhang, X., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30806 · Cited by 141

Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

Stewart, D. J., Issa, J. J., Kurzrock, R., Nunez, M. I., Jelı́nek, J., Hong, D. S., Oki, Y., Guo, Z., Gupta, S. K., & Wistuba, I. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2196 · Cited by 139

Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Hirsh, V. (2011) · Current Oncology · doi:10.3747/co.v18i3.877 · Cited by 138

Increased Toxicity With Gefitinib, Capecitabine, and Radiation Therapy in Pancreatic and Rectal Cancer: Phase I Trial Results

Czito, B. G., Willett, C. G., Bendell, J. C., Morse, M. A., Tyler, D. S., Fernando, N. H., Mantyh, C. R., Blobe, G. C., Honeycutt, W., Yu, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1749 · Cited by 138

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Dahabreh, I. J., Linardou, H., Siannis, F., Kosmidis, P., Bafaloukos, D. I., & Murray, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1660 · Cited by 137

Molecular genetics of lung cancer in people who have never smoked

Subramanian, J., & Govindan, R. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70174-8 · Cited by 132

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

Solit, D. B., She, Y., Lobo, J. M., Kris, M. G., Scher, H. I., Rosen, N. X., & Sirotnak, F. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1347 · Cited by 132

Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Goldberg, S. B., Oxnard, G. R., Digumarthy, S., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0168 · Cited by 130

Novel Therapeutic Targets in Non-small Cell Lung Cancer

Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first‐line treatment of patients with glioblastoma multiforme

Hainsworth, J. D., Ervin, T. J., Friedman, E. K., Priego, V. M., Murphy, P. B., Clark, B. L., & Lamar, R. E. (2010) · Cancer · doi:10.1002/cncr.25275 · Cited by 131

Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells

Yamaguchi, H., Hsu, J. L., Chen, C., Wang, Y., Hsu, M., Chang, S.-S., Du, Y., Ko, H., Herbst, R. S., & Hung, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2621 · Cited by 133

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131

Pharmacodynamic Separation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy in Non–Small-Cell Lung Cancer

Davies, A. M., Ho, C., Lara, P. N., Mack, P. C., Gumerlock, P. H., & Gandara, D. R. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.021 · Cited by 130

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

Jakacki, R. I., Hamilton, M., Gilbertson, R. J., Blaney, S. M., Tersak, J. M., Krailo, M., Ingle, A. M., Voss, S. D., Dancey, J. E., & Adamson, P. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2306 · Cited by 130

The Evolution of Therapies in Non-Small Cell Lung Cancer

Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 126

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131

Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation

Choong, N. W., Dietrich, S., Seiwert, T. Y., Tretiakova, M., Nallasura, V., Davies, G. C., Lipkowitz, S., Husain, A. N., Salgia, R., & Ma, P. C. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0400 · Cited by 124

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Soria, J., Massard, C., & Chevalier, T. L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq204 · Cited by 123

Where next for gefitinib in patients with lung cancer?

Blackhall, F. H., Ranson, M., & Thatcher, N. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70725-2 · Cited by 123

Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers

Lee, K. H., Han, J., Lee, H. G., Lee, J. J., Lee, E. K., Kim, H. Y., Kim, H. K., Hong, E. K., & Lee, J. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2149 · Cited by 121

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Gaafar, R. M., Surmont, V. F. M., Scagliotti, G. V., van Klaveren, R. J., Papamichael, D., Welch, J. J., Hasan, B., Torri, V., & van Meerbeeck, J. P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.045 · Cited by 118

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122

The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells

Milligan, S. A., Burke, P., Coleman, D. T., Bigelow, R. L. H., Steffan, J. J., Carroll, J. L., Williams, B. J., & Cardelli, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0109 · Cited by 118

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Harandi, A., Zaidi, A., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116

Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy

Pytel, D., Śliwiński, T., Popławski, T., Ferriola, D., & Majsterek, I. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787047752 · Cited by 115

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Wang, Y., Schmid‐Bindert, G., & Zhou, C. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011427927 · Cited by 124

Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy

Škubník, J., Pavlíčková, V. S., Ruml, T., & Rimpelová, S. (2021) · Plants · doi:10.3390/plants10030569 · Cited by 121

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

de Groot, J., Gilbert, M. R., Aldape, K., Hess, K. R., Hanna, T., Ictech, S. E., Groves, M. D., Conrad, C., Colman, H., Puduvalli, V. K., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9637-y · Cited by 116

Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer

He, C., Liu, M., Zhou, C., Zhang, J., Ouyang, M., Zhong, N., & Xu, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.24653 · Cited by 111

Immunotherapy in the treatment of non-small cell lung cancer

Sundar, R., Soong, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.005 · Cited by 114

Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer

Lara-Guerra, H., Waddell, T. K., Salvarrey, A. M., Joshua, A. M., Chung, C. T. ‐., Paul, N. S., Boerner, S. L., Sakurada, A., Ludkovski, O., Ma, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3370 · Cited by 113

50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer

Wakelee, H. A., Kelly, K. L., & Edelman, M. J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.177 · Cited by 114

Strategies for modern biomarker and drug development in oncology

Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112

Drug interactions with solid tumour-targeted therapies

Thomas‐Schoemann, A., Blanchet, B., Bardin, C., Noé, G., Boudou, P., Vidal, M., & Goldwasser, F. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.007 · Cited by 112

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors

Morelli, M. P., Cascone, T., Troiani, T., Vita, F. D., Orditura, M., Laus, G., Eckhardt, S. G., Pepe, S., Tortora, G., & Ciardiello, F. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi910 · Cited by 112

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 115

Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

Loriot, Y., Perlemuter, G., Malka, D., Penault-Llorca, F. M., Boige, V., Deutsch, É., Massard, C., Armand, J. P., & Soria, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1087 · Cited by 110

Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research

Belani, C. P., Marts, S. A., Schiller, J. H., & Socinski, M. A. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.008 · Cited by 110

Targeting EGFR in Lung Cancer: Current Standards and Developments

Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

Sugawara, S., Oizumi, S., Minato, K., Harada, T., Inoue, A., Fujita, Y., Maemondo, M., Yoshizawa, H., Ito, K., Gemma, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv063 · Cited by 110

Strategies to design clinical studies to identify predictive biomarkers in cancer research

Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development

Gridelli, C., Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., & Ciardiello, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-840 · Cited by 109

Tobacco Smoking and Lung Cancer : Perception Changing Facts = تدخين التبغ و سرطان الرئة : إدراك تغير الحقائق

Furrukh, M. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003255 · Cited by 117

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas

Đačić, S., Shuai, Y., Yousem, S. A., Ohori, P. N., & Nikiforova, M. N. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.154 · Cited by 108

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Philips, G. K., Halabi, S., Sanford, B. L., Bajorin, D. F., & Small, E. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn749 · Cited by 108

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1593 · Cited by 109

Diarrhea associated with afatinib: an oral ErbB family blocker

Yang, J. C., Reguart, N., Barinoff, J., Köhler, J., Uttenreuther‐Fischer, M., Stammberger, U. M., O’Brien, D., Wolf, J., & Cohen, E. E. W. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.31 · Cited by 107

Mechanisms of tumor resistance to EGFR-targeted therapies

Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109

Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials

Šeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 110

Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study

Li, N., Ou, W., Xiong, Y., Sun, H.-B., Zhang, L., Fang, Q., Zhang, S.-L., Wang, B.-X., & Wang, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3586-9 · Cited by 106

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

Ilson, D. H., Kelsen, D. P., Shah, M. A., Schwartz, G. K., Levine, D. A., Boyd, J. A., Capanu, M., Miron, B., & Klimstra, D. S. (2010) · Cancer · doi:10.1002/cncr.25602 · Cited by 105

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments

Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 111

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

O’Leary, C. G., Gasper, H. M., Sahin, K. B., Tang, M., Kulasinghe, A., Adams, M. N., Richard, D. J., & O'Byrne, K. J. (2020) · Pharmaceuticals · doi:10.3390/ph13100273 · Cited by 114

Lung cancer in never smokers: Change of a mindset in the molecular era

Lee, Y. J., Kim, J.-H., Kim, S. I., Ha, S., Mok, T. S. K., Mitsudomi, T., & Cho, B. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.013 · Cited by 107

Rash as a Surrogate Marker for Efficacy of Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

Perez-Soler, R. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.s.008 · Cited by 103

Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Hirsh, V., Blais, N., Burkes, R. L., Verma, S., & Croitoru, K. (2014) · Current Oncology · doi:10.3747/co.21.2241 · Cited by 102

Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years

Čufer, T., Ovčariček, T., & O'Brien, M. E. R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.021 · Cited by 104

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875

Beyond the Tribute Trial: Integrating Her1/Egfr Tyrosine Kinase Inhibitors With Chemotherapy In Advanced Nsclc

Reck, M. (2006) · Future Oncology · doi:10.2217/14796694.2.1.47 · Cited by 9

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE

Miller, V. A., Herbst, R. S., Prager, D., Fehrenbacher, L., Hermann, R., Hoffman, P. C., Johnson, B. E., Sandler, A. B., Kris, M. G., & Ramies, D. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7061 · Cited by 51

Select Clinical Trials of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer with Emphasis on Phase III Outcomes

Fuster, L. M. B., & Sandler, A. B. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.011 · Cited by 46

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7010 · Cited by 311